
|Articles|February 15, 2004
QLT lowers verteporfin cost after CMS cuts reimbursement
Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















